Lenalidomide ‘best maintenance option’ for multiple myeloma

Lenalidomide maintenance improved PFS and OS among patients with newly diagnosed multiple myeloma compared with other maintenance treatments, according to results from a network meta-analysis.

“The continuous therapy approach has been evaluated extensively in patients with newly diagnosed multiple myeloma, across age groups and treatment strategies upfront, in several trials with different designs,” Francesca Gay, MD, PhD,hematologist at the myeloma unit of the Azienda Ospedaliero-Universitaria Città della Salute e della Scienza in Italy, and colleagues wrote. “It generally consists of multiagent chemotherapy for a fixed time, followed by a less intensive but prolonged maintenance treatment.

“Despite the well-recognized importance of maintenance, there is no evidence demonstrating the overall superiority of regimen over the others, owing to the lack of direct or indirect comparisons,” they added.

Read more here: https://www.healio.com/hematology-oncology/myeloma/news/in-the-journals/%7B8c1fda0e-e520-44be-81f4-9956ea9045e0%7D/lenalidomide-best-maintenance-option-for-multiple-myeloma